Portfolio

• Our strength comes from offering one of the most comprehensive product portfolios in CNS pharmaceuticals in Europe
• We are current leaders(*) in Antiepileptics, Antiparkinson, Antipsychotics, Antidepressants and Antialzheimer 
  and we continue to grow in other therapeutic indications
• Our product portfolio includes >130 CNS molecules in the categories of Analgesics, Antidementia agents, Antidepressants, Antiepileptics, Antiparkinson agents, Antipsychotics, Anxiolytics/Hypnotics and other CNS categories

(*) Source: IQVIA – Global MIDAS

• We are experts in improving existing pharmaceutical forms and in upgrading new products. In some cases, new patient-friendly products and formulations are developed at the request of, and in close consultation with, medical specialists

• Our extensive portfolio includes not only high-turnover products and conventional pharmaceutical forms but, thanks to Neuraxpharm’s intense patient focus, we can also provide less popular preparations and offer products in a comprehensive, patient-friendly range of active substances in well-tolerated forms, along with a very wide range of dosages for personalised treatment

• It is part of Neuraxpharm’s very identity to be able to offer patients and medical specialists affordable cutting-edge CNS drugs

• Medicines are improved by innovative advancements in their pharmaceutical forms and by more practical dosing

• The integration of all the companies within Neuraxpharm allows us to establish both growth and cross-business synergies in many strategic aspects such as R&D, manufacturing, procurement, cross-licensing and geographical expansion